Peri Implantitis
Conditions
Brief summary
This study is designed to assess the safety and effectiveness of BonyPid-500TM implantation for intrabony peri-implantitis defects. BonyPid-500™ is a bone graft substitute, which contains an antibiotic drug - doxycycline, and is intended for filling and reconstruction of bone defects caused by peri-implantitis.
Detailed description
This is a pilot, randomized, single-blind, two arm controlled, multicenter study in subjects undergoing surgical treatment for peri-implantitis disease. Eligible subjects will undergo a surgical treatment and be randomly assigned during surgical intervention (after flap opening) in a 1:1 ratio to adjunct BonyPid-500TM implantation or no BonyPid-500TM implantation. Randomization will be stratified by site and number of eligible implants, i.e., single or multiple. The study population includes male and female subjects, 20 - 80 years of age at screening, diagnosed with peri-implantitis and recommended for surgical treatment of peri-implantitis disease. Up to 77 subjects will be enrolled to this study which will be conducted in two medical centers in Israel.
Interventions
DEVICEBonyPid 500TM implantation concomitantly to SOC treatment
BonyPid 500TM implantation concomitantly to SOC treatment
OTHERSOC treatment only
Standard of care treatment (Manual and ultrasonic debridement, and surface decontamination)
Sponsors
MIS Implant Technologies, Ltd
PolyPid Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
20 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Male and Female subjects, 20 - 80 years of age at screening. * Females of childbearing potential must have a negative urine pregnancy test before radiographs, dental hygienist cleaning, and surgical procedure (Note: Females of childbearing age must agree to use a highly effective method of contraception consistently and correctly for the duration of the study period). * Subjects with a minimum of one osseo-integrated implant with peri-implantitis. * Subjects with at least one eligible implant within the surgical area. * Subjects with bleeding on probing of selected implant with or without suppuration. * Subjects with selected implant(s) having radiographic evidence, according to X-rays, of: 1. Intrabony defect 2. Bone loss ≥ 3 mm 3. Minimum of 2 mm of bone at implant apex. * Subjects must be willing and able to provide a written informed consent prior to any protocol specific procedures being performed and comply with protocol requirements.
Exclusion criteria
* Subjects with hydroxyapatite (HA) coated implants, titanium plasma spray implants. * Subjects with a distance between implants \< 3 mm, or \< 2 mm between implant and tooth. * Subjects with implants supporting removable dentures. * Subjects presenting with severe active periodontitis. * Subjects with poor oral hygiene. * Subjects with selected implant(s) with radiographic evidence of horizontal bone loss only. * Subjects suffering from Type 1 (insulin dependent) diabetes; or uncontrolled Type 2 diabetes. Diabetic subjects must provide a statement from a physician regarding the status of diabetes, in addition to a recent (within 3 months) documented Hemoglobin (Hgb) A1c blood test of \< 6.5%. * Pregnant women or women who intend to become pregnant during the study period, or breastfeeding women. * Subjects with known allergy or contraindication to tetracycline(s). * Subjects who are current smokers or who were smokers within 3 months prior to screening. * Subjects who were under oral or local antibiotic therapy in the last 4 weeks prior to study enrollment. * Subjects treated for at least 2 weeks with any medication known to affect soft tissue condition within one month prior to study enrollment (e.g., Phenytoin, Cyclosporine, Coumadin, and NSAIDs). * Subjects treated with Oral or IV use of doxycycline in the last four weeks prior to screening. * Subjects with presence of active systemic infectious diseases such as: hepatitis, HIV, or a history of tuberculosis. * Subjects with any condition, which in the opinion of the Investigator, would place the subject at risk or influence the conduct of the study or interpretation of results. * Subjects who are incapable of following the study schedule for any reason, per the Investigator's discretion. * Subjects who are currently enrolled, recently participated (within 30 days prior to screening), or planning to enroll in another study that may conflict with protocol requirements or may confound the subject results in this trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety: AEs (adverse events) as reported by the subject or observed by the Investigator, | 12 months | All AEs including any change in medical or dental status. |
| Effectiveness: the change in Pocket Probing Depth (cPPD) from baseline to 6 months, measured in mm. | 6 months | The primary effectiveness endpoint of the study is the change in Pocket Probing Depth (cPPD) from baseline to 6 months, measured in mm. |
Countries
Israel
Outcome results
None listed